| Autor: |
Gilbert Zakine, Anne Perruisseau-Carrier, Corinne Becker, Frédéric Sedel, Luc Téot, Denis Barritault |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Aesthetic Surgery Journal Open Forum, Vol 5 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2631-4797 |
| DOI: |
10.1093/asjof/ojad031 |
| Popis: |
Abstract BackgroundCACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic that accelerates tissue healing by stabilizing matrix proteins and protecting heparin-binding growth factors. In humans, an open self-controlled study suggested that the topical application of CACIPLIQ20 optimizes skin healing following surgery. ObjectivesTo expand previous findings using a different CACIPLIQ20 administration regimen. MethodsTwenty-four females were referred for breast-reduction surgery. Each patient had their own control with 1 CACIPLIQ20-treated and 1 saline-treated control breast. The treated side (right or left) was randomly assigned by the operating surgeon. Scar appearance was assessed by 6 independent raters using a global visual scar comparison scale based on scar photographs. All raters were blinded toward the CACIPLIQ20-treated side. ResultsThe follow-up period following surgery ranged from 1 to 12 months with a median follow-up of 6 months. Overall, there was a mean improvement of 15.2% (SD = 26.7) in favor of CACIPLIQ20 (P ConclusionsIn conclusion, CACIPLIQ20 could represent an interesting scar prophylactic therapy, based on a single administration at the time of surgery, and without any known adverse effects. Level of Evidence: 3 |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
